Lung cancer remains the leading cause of cancer-related deaths worldwide. It is broadly classified into small cell lung cancer and non-small cell lung cancer. The latter accounts for about 80% of the cases. According to the new study results presented at the European Lung Cancer Congress 2025, Tagrisso has reinforced as the backbone therapy for EGFR-mutated lung cancer. The data showed that adding savolitinib or datapotamab deruxtecandlnk at the time of lung cancer progression can help prolong responses to the treatment.
The study demonstrated the role of Tagrisso as monotherapy as well as the backbone for novel combinations across stages and settings of epidermal growth factor receptor-mutated NSCLC. The highlights of the study are discussed here.
LAURA Phase III trial of Tagrisso in unresectable, Stage III EGFRm NSCLC after chemo radiotherapy. ORCHARD Phase II platform trial of Tagrisso and Datroway in advanced EGFRm NSCLC. FLAURA2 Phase III Trial of Tagrisso plus chemotherapy as first-line treatment for advanced EGFRm NSCLC. SAVANNAH Phase II trial of Tagrisso and Orpathys in advanced EGFRm NSCLC with high levels of MET overexpression following disease progression on first-line Tagrisso. Tagrisso has demonstrated encouraging survival trend in Stage III setting in LAURA trial. The updated results have shown an improved trend towards benefits with Tagrisso in comparison to placebo in patients with Stage III NSCLC. The trial will continue to access overall survival benefit with Tagrisso as a key endpoint athlete the final analysis. Previously, Tagrisso has demonstrated a significant and highly clinical meaningful improvement in progression-free survival.
Tagrisso has been used to treat lung cancer patients worldwide and AstraZeneca continues to explore Tagrisso as a treatment for patients across multiple stages of EGFRm NSCLC. Tagrisso is also being investigated in the early-stage adjuvant resectable setting in ADAURA2 Phase III trial.
The information shared in this blog is for educational purposes only.
Subscribe to our newsletter or follow us on Facebook or Twitter today to stay informed and never miss an update!